ÂÜÀòÂÒÂ×

Mary Canning has extensive work experience in the field of life sciences and venture capital. Mary is currently a Partner at Epidarex Capital since January 2023, where they previously held the positions of Principal from May 2019 to January 2023 and Associate from February 2013 to May 2019. Mary also serves as a Director at Transine Therapeutics, Caldan Therapeutics, and LUNAC Therapeutics, starting in April 2022, April 2021, and September 2019 respectively. Prior to their current roles, Mary worked as a Business Manager at MRC Technology from February 2010 to February 2013, where they were responsible for identifying, protecting, and exploiting intellectual property. Before that, they served as a Senior Executive at Scottish Enterprise from August 2005 to February 2010, overseeing the life science portfolio for the Proof of Concept Programme. Mary's diverse background also includes being a Medici Fellow at the University of Nottingham from September 2004 to August 2005.

From 1996 to 2000, Mary Canning pursued their higher education at The University of Edinburgh. During this time, they successfully completed their PhD in Molecular Genetics.